Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer

BACKGROUND: The phase 3 KATHERINE trial demonstrated significantly improved invasive disease–free survival with adjuvant trastuzumab emtansine (T‐DM1) versus trastuzumab in patients with HER2‐positive early breast cancer and residual invasive disease after neoadjuvant chemotherapy plus HER2‐targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Conte, PierFranco, Schneeweiss, Andreas, Loibl, Sibylle, Mamounas, Eleftherios P., von Minckwitz, Gunter, Mano, Max S., Untch, Michael, Huang, Chiun‐Sheng, Wolmark, Norman, Rastogi, Priya, D’Hondt, Veronique, Redondo, Andrés, Stamatovic, Ljiljana, Bonnefoi, Hervé, Castro‐Salguero, Hugo, Fischer, Hans H., Wahl, Tanya, Song, Chunyan, Boulet, Thomas, Trask, Peter, Geyer, Charles E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317721/
https://www.ncbi.nlm.nih.gov/pubmed/32286687
http://dx.doi.org/10.1002/cncr.32873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317721/
https://www.ncbi.nlm.nih.gov/pubmed/32286687
http://dx.doi.org/10.1002/cncr.32873

Ejemplares similares